Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2012

View Archived Issues

Tragara multikinase inhibitor may be beneficial to treat triple-negative breast cancer

Phase II data presented on PEGylated therapy in previously treated metastatic breast cancer

Phase II results disclosed on PD-0332991

Dual ERK inhibitor shows promise as triple-negative breast cancer therapy

Two Cellceutix products expected to enter clinic this year

Phase II trial assesses proprietary Exelixis drug in metastatic breast cancer

New HCV NS5A inhibitors disclosed by Presidio Pharmaceuticals

Apricus Biosciences and Stellar Pharmaceuticals sign license agreement for MycoVa

Dosing completed in phase II trial of low-dose oral Proellex

Isotechnika licenses voclosporin to Vifor Pharma for certain regions

Euroscreen prepares new agents for diabetes and associated conditions

Novel inhibitors of cytochrome P450 enzymes synthesized by Angion Biomedica

Arrow Therapeutics claims novel HCV NS5B inhibitors

ACH-1625 receives FDA fast track status

Enanta Pharmaceuticals designs new compounds for hepatitis C virus infection

Quark Pharmaceuticals reports first-in-human data on siRNA drug candidate

Researchers at Albany Molecular Research patent novel GlyT-1 inhibitors

Cardiokine acquired by Cornerstone Therapeutics

Alkermes reports phase I/II ALKS-5461 study results

Alnylam reports preliminary results from phase I ALN-PCS trial

Alchemia treats first patient in pivotal phase III HA-irinotecan trial

Celldex begins phase II study of rindopepimut

PolyMedix completes enrollment in PMX-30063 study

Acacia Pharma begins phase II APD-421 trial

Biogen Idec and Isis enter collaboration on antisense drug for SMA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...